E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Active Systemic Lupus Erythematosus |
|
E.1.1.1 | Medical condition in easily understood language |
Active Systemic Lupus Erythematosus |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042945 |
E.1.2 | Term | Systemic lupus erythematosus |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythomatosus in male and female adults. Patients who qualify will be randomized to either active BMS-931699 or placebo for up to 24 weeks. Disease activity and safety will be assessed over the course of the study through laboratory values, various rating scales accepted in systemic lupus erythomatosus studies and patient self reporting. |
|
E.2.2 | Secondary objectives of the trial |
- proportion of subjects who demonstrate an improvement in their SLE Responder Index assessments
- proportion of subjects who improve their scores of disease activity
- change in the use of other medications
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenetics Blood Sample Amendment -Number 1 dated 20-Aug-14
The objective of this Amendment is to permit the collection and storage of blood samples for use
in future exploratory pharmacogenetic research. Bristol-Myers Squibb will use DNA obtained
from the blood sample and health information collected from the main clinical trial, IM128027 to
study the association between genetic variation and drug response. |
|
E.3 | Principal inclusion criteria |
Male or female aged between 18 to 70 (included)
Diagnosed with active systemic lupus erythomatosus by a doctor
Disease must be in patient’s joints or on the skin at a minimum
Taking other medications is allowed but some are excluded
|
|
E.4 | Principal exclusion criteria |
Diagnosed with active lupus nephritis, multiple sclerosis or rheumatoid arthritis
Diagnosed with active tuberculosis or an ongoing infection with a bacteria or a virus
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of subjects who achieve a BICLA response (BICLA response rate) at Day 169. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary endpoint will be assessed at Day 169. |
|
E.5.2 | Secondary end point(s) |
- proportion of subjects who demonstrate an improvement in their SLE Responder Index assessments
- proportion of subjects who improve their scores of disease activity
- change in the use of other medications
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will be assessed at Day 85 and Day 169. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
Chile |
Colombia |
France |
Germany |
Hungary |
Italy |
Korea, Republic of |
Mexico |
Poland |
Puerto Rico |
Romania |
South Africa |
Spain |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 4 |